First batch of bluetongue Bovilis BTV8 vaccine released to supply Northern
BOXMEER, Netherlands, April 30 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health (NYSE: SGP) released the first batch of Bovilis BTV8 vaccine against bluetongue to supply in Northern Europe. The animal health company, combining after the acquisition in 2007 the strength of Intervet and Schering-Plough Animal Health, is not only the world market leader in the production of animal health vaccines, but also one of the world's leaders in the field of animal health.
"Within the animal health sector, there has been a recent emphasis on prevention rather than treatment," says Ruurd Stolp, D.V.M., Ph.D., Senior Vice President and President Global Animal Health. "Our goal is to develop innovative vaccines that address unmet needs and improve disease protection as well as the duration of that protection. When animal diseases are not prevented, the social economic and environmental costs to humans are potentially significant." One prominent example is bluetongue, a devastating disease of ruminants that emerged in Northern Europe since the summer of 2006. The combined animal health unit is uniquely positioned to respond to this need and to deliver effective and timely care.
Intervet/Schering-Plough Animal Health has now released the first batch
of bluetongue vaccine for sheep and cattle, Bovilis BTV8, fulfilling firm
orders received from a number of countries within Europe. Stolp: "We put
great effort into the development of our safe and efficacious Bovilis BTV8
vaccine to meet the urgent need as quickly as possible and we are pleased
that production is on track, so that we are able to deliver th
|SOURCE Intervet/Schering-Plough Animal Health|
Copyright©2008 PR Newswire.
All rights reserved